Viking Therapeutics Культура компании

Dr. Brian Lian, Ph.D., has been the Chief Executive Officer and President at Viking Therapeutics, Inc. since September 24, 2012. Dr. Lian served as Managing Director and Senior Research Analyst at SunTrust Robinson Humphrey, Inc., Research Division. He served as a Managing Director and Senior Biotechnology Analyst of Healthcare Group of Global Hunter Securities, LLC, Research Division. He served as an Equity Analyst of BNP Paribas Fortis, Research Division. He served as Research Analyst at CIBC World Markets Corp., American Research Division. He served as Senior Biotechnology Analyst at Oppenheimer & Co. Inc., Research Division. He served as Senior Research Analyst at CIBC World Markets Inc., Research Division. He served as Senior Research Analyst at Fortis Securities Inc., Research Division. He served as Managing Director of Healthcare Research at Meridian Equity Partners, Inc., Research Division and Meridian Equity Partners, Inc. He served as Research Scientist at Amgen Inc. He joined Meridian Equity Partners, Inc. from The Agave Group LLC, a New York-based research boutique and has 7 years of experience covering the healthcare sector. From 2003 to 2008, he covered biotechnology and specialty pharmaceutical companies. He served as Senior Research Analyst for Biotechnology at Fortis Bank. In 2008, he founded The Agave Group, a healthcare research platform to serve portfolio managers, analysts, traders and corporate clients. He was a Research Scientist at Microcide Pharmaceuticals, where he worked in collaboration with Pfizer to identify novel classes of antibiotics. He worked at The Agave Group LLC. He served as Interim Chairman of Viking Therapeutics, Inc. until June 4, 2015. He has been a Director at Viking Therapeutics, Inc. since September 24, 2014. He served as an Executive Director at Oppenheimer & Co. Inc., Research Division and at CIBC World Markets Inc., Research Division. He co-authored research in organic chemistry, medicinal chemistry, biochemistry and chemical physics and contributed to texts in organic and advanced organic chemistry. Dr. Lian received his Ph.D. in Organic Chemistry from The University of Michigan, an M.B.A. in Finance and Accounting from Indiana University and a B.A. in Chemistry from Whitman College.

Dr. Hiroko Masamune, Ph.D serves as Senior Vice President of Pharmaceutical Development at Viking Therapeutics, Inc. since June 2014. Dr. Masamune has over 20 years of pharmaceutical development experience. Dr. Masamune served as a Vice President of Product Development at Aires Pharmaceuticals, Inc. Before joining Aires, Dr. Masamune served as Vice President, Product Development at Palkion Inc. At Palkion, she was responsible for all aspects of preclinical development and served as its alliance manager. From 2005 to 2008, Dr. Masamune served as a Senior Director of Pharmaceutical Sciences at Neurogen Corp., where she oversaw two Phase 2 candidates for the treatment of insomnia and Parkinson's disease/restless leg syndrome, one Phase 1 candidate for the treatment of obesity and a range of early development and late discovery candidates. She spent 15 years in drug development at Pfizer. She earned a B.S. in Organic Chemistry from the University of Wisconsin and a Ph.D. in Organic Chemistry from the University of California, Los Angeles. Dr. Masamune completed her post-doctoral fellowship in Organic Chemistry at M.I.T.

Mr. Michael Morneau has been the Chief Accounting Officer and Vice President of Finance at Trius Therapeutics, Inc. since August 2010. Mr. Morneau has been the Chief Financial Officer at Viking Therapeutics, Inc. since May 2014 and serves its Principal Accounting Officer. Mr. Morneau has over 20 years of accounting and financial experience at public and private companies in the biotechnology and accounting industries. Prior to Viking, he served as Vice President of Finance and Chief Accounting Officer at Trius Therapeutics, Inc., a subsidiary of Cubist Pharmaceuticals, Inc., a pharmaceutical company, following Cubist's acquisition of Trius. Prior to Trius, he served as Director of Lilly Research Labs Finance at Eli Lilly and Company, a pharmaceutical company. Prior to Eli Lilly, he served as Director of Finance and Accounting at SGX Pharmaceuticals, Inc., a biotechnology company, which was acquired by Eli Lilly. Prior to SGX, he served as Controller at Momenta Pharmaceuticals, Inc., a biotechnology company. Mr. Morneau earned his MBA and Master of Arts in accounting from New Hampshire College and a BA in mathematics from the University of New Hampshire.

Mr. Gregory S. Zante, also known as Greg, CPA, has been Vice President of Finance and Operations at Viking Therapeutics, Inc. since January 5, 2017. Mr. Zante is responsible for forecasting, scenario analyses, financing strategies, business development support and operational activities. He served as the Chief Financial Officer and Vice President of Administration at Dance BioPharm Inc. since July 2013 and also served as its Principal Accounting Officer. Mr. Zante served as Vice President of Administration and Finance of Sangamo Biosciences, Inc. from August 2003 to June 2013. He served as Senior Director of Administration and Finance of Sangamo Biosciences, Inc. since August 2003 and also served as its Principal Financial Officer until December 2007 and Principal Accounting Officer. Prior to Sangamo, Mr. Zante served as Director, Finance and Administration of Calyx Therapeutics, Inc. from December 2001 to 2003. From October 1993 to December 2001, he held senior financial managerial positions in several companies including Matrix Pharmaceuticals, Inc. He served as a Senior Staff Accountant of Ernst & Young LLP from October 1993 to November 1995. He has more than 20 years of accounting and financial experience at public and private companies in the biotechnology and accounting industries. Mr. Zante holds a B.A. in Business Economics and Managerial Accounting from the University of California, Los Angeles and is a Certified Public Accountant in the state of California.

Ms. Amy Broidrick has been Senior Vice President of Corporate Development at Viking Therapeutics, Inc. since January 05, 2017. Ms. Broidrick leads business development and partnering efforts at Viking. She has 22 years of pharmaceutical industry experience. Ms. Broidrick is a seasoned industry executive credited with launching and exceeding profit targets for blockbuster brands including Celebrex??? in the United States and Zetia??? and VYTORIN??? across Europe, the Middle East and Africa. She served as Vice President and Head of Global Marketing Excellence and Business Innovation at EMD Serono, Inc, part of Merck KGaA (Germany). Ms. Broidrick served as Vice President and Head of Marketing andCommercialization at Arena Pharmaceuticals. She has also held roles of increasing responsibility at Merck & Co. and Pfizer (formerly GD Searle).

Mike Morneau serves as the Vice President, Finance and Administration of Viking Therapeutics, Inc.. Mike started at Viking Therapeutics, Inc. in April of 2018. Mike currently resides in Greater San Diego Area.

Hiroko Masamune serves as the Chief Development Officer of Viking Therapeutics, Inc.. Hiroko started at Viking Therapeutics, Inc. in July of 2018. Hiroko currently resides in Greater San Diego Area.

Marianne Mancini serves as the SVP, Clinical Operations of Viking Therapeutics, Inc.. Marianne currently resides in the Greater San Diego Area.